Merger brings U.S. management and presence, cash to develop compelling late-stage asset
Lead candidate AL102 being evaluatedin ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors
Ayala and Advaxis stockholders will respectively own approximately 62.5% and37.5%
Combined Company to Seek Uplisting to Nasdaq
Conference Call and Webcast today at 8:00am ET
Ayala Pharmaceuticals, Inc a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc. (OTCQX: ADXS) (Advaxis), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes, today announced that they have entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala
